Physician profile
Vikarma Wayne Brooks
NPI 1811559024
$1,531.60
in general payments reported to CMS, 2019-2025
11 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $213 · 2021: $169 · 2022: $322 · 2023: $254 · 2024: $298 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $382.10 | 2020-2025 | Clariti Contact Lens, Myday Contact Lens |
| Notal Vision, INC. | $288.69 | 2022-2024 | Foresee Home |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $246.73 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $158.67 | 2024-2025 | Infuse |
| Johnson & Johnson Vision Care, INC. | $146.94 | 2020-2023 | Acuvue |
| Alcon Vision LLC | $100.52 | 2023-2025 | Hydrus Microstent, Tryptyr |
| Lkc Technologies, INC. | $83.33 | 2023 | |
| Sun Pharmaceutical Industries INC. | $60.99 | 2022-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $30.44 | 2021-2022 | |
| Oyster Point Pharma, INC. | $20.85 | 2022 | |
| Visioneering Technologies, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikarma Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.